Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001)

Phase 1

Completed

• Conditions: Diffuse Large B Cell Lymphoma; Mantle-cell Lymphoma; Non-Hodgkin Lymphoma; Follicular Lymphoma; Primary Mediastinal B-cell Lymphoma
• Interventions: Biological: JCAR017 (lisocabtagene maraleucel) 2-dose schedule; Biological: JCAR017 (lisocabtagene maraleucel) single-dose schedule

• Registration Number: NCT02631044
• Lead Sponsor: Juno Therapeutics, a Subsidiary of Celgene

Brief Summary

This open-label Phase 1 study will evaluate the safety, PK, and antitumor activity of modified T cells (JCAR017) administered to adult patients with relapsed or refractory B-cell NHL. The dose and schedule of JCAR017 will be evaluated and modified, as needed, for safety and antitumor activity. We will also determine how long the modified T cells stay in the patient's body and how well JCAR017 works in treating patients with non-Hodgkin's lymphoma whose disease has come back or has not responded to treatment.

Detailed Description

This is an open-label, multicenter Phase 1 study to determine the safety, pharmacokinetics (PK), and antitumor activity of JCAR017 in adult patients with relapsed or refractory diffuse large B cell lymphoma (DLBCL), primary mediastinal B-cell lymphoma (PMBCL), follicular lymphoma Grade 3B, and mantle cell lymphoma (MCL). This study will evaluate and refine the dose and schedule of JCAR017 to optimize safety and antitumor activity. A dose-confirmation group or groups will further evaluate the safety and efficacy of JCAR017 at the recommended regimen(s).

Upon successful generation of JCAR017 product, participants will receive treatment with one or more cycles of JCAR017 therapy. Each cycle will include lymphodepleting chemotherapy followed by one or two doses of JCAR017 administered by intravenous (IV) injection.

The follow-up period for each participant is approximately 24 months after the final JCAR017 infusion. Long-term follow-up for survival, toxicity, and viral vector safety will continue under a separate long-term follow-up protocol per health regulatory authority guidelines, currently up to 15 years after the last JCAR017 infusion.

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations
|
Related News

Study Timeline

• Study First Submitted: 2015-12-11
• Study First Submitted QC: 2015-12-11
• Study First Posted: 2015-12-15
• Study Start: 2016-01-06
• Primary Completion: 2024-05-16
• Study Completion: 2024-05-16
• Status Verified: 2024-06
• Last Update Submitted: 2024-06-26
• Last Update Posted: 2024-06-27

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 387

Inclusion Criteria

1. Age ≥18 years

2. Relapsed or refractory B-cell NHL, including

   1. DLBCL cohort (no longer enrolling): DLBCL, not otherwise specified (NOS; includes transformed DLBCL from indolent histology [tDLBCL]), high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements with DLBCL histology (Swerdlow 2016), primary mediastinal B-cell lymphoma (PMBCL), and follicular lymphoma Grade 3B. Subjects must have been treated with an anthracycline and rituximab (or other CD20-targeted agent) and have relapsed or refractory disease after at least 2 lines of systemic therapy or after auto-HSCT.
   2. MCL cohort: MCL (diagnosis must be confirmed with cyclin D1 expression or evidence of t(11;14) by cytogenetics, fluorescent in situ hybridization [FISH], or PCR) with relapsed or refractory disease after at least 2 prior lines of systemic MCL therapy. Subjects must have been treated with an alkylating agent, Bruton's tyrosine kinase inhibitor (BTKi), and rituximab (or other CD20-targeted agent).

3. PET-positive disease by Lugano classification

4. Archived tumor biopsy tissue available from the last relapse and corresponding pathology report available or, if at least one tumor-involved site is deemed accessible at time of screening, willing to undergo pre-treatment biopsy (excisional when possible) for disease confirmation. If a subject has never had a complete response, a sample from the most recent biopsy is acceptable.

5. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

6. Adequate bone marrow, renal, hepatic, pulmonary, and cardiac function

7. Adequate vascular access for leukapheresis procedure

8. Participants who have received previous CD19-targeted therapy must have CD19-positive lymphoma confirmed on a biopsy since completing the prior CD19-targeted therapy.

9. Participants must agree to use appropriate contraception.

Read More

Exclusion Criteria

1. Active central nervous system (CNS)-only involvement by malignancy (note: participants with secondary CNS involvement are allowed on study)

2. History of other primary malignancy not in remission for at least 2 years (The following are exempt from the 2-year limit: nonmelanoma skin cancer, definitively treated stage 1 solid tumor with low risk for recurrence, curatively treated localized prostate cancer, and cervical carcinoma in situ on biopsy or a squamous intraepithelial lesion on Pap smear)

3. Treatment with alemtuzumab within 6 months of leukapheresis or fludarabine or cladribine within 3 months of leukapheresis

4. Active hepatitis B, hepatitis C, or Subjects with a history of or active human immunodeficiency virus (HIV) infectionare excluded. Subjects with active hepatitis B, or active hepatitis C are also excluded. Subjects with a negative PCR assay for viral load for hepatitis B or C are permitted. Subjects positive for hepatitis B surface antigen and/or anti-hepatitis B core antibody with negative viral load are eligible and should be considered for prophylactic antiviral therapy

5. Uncontrolled systemic fungal, bacterial, viral, or other infection

6. Presence of graft-vs-host disease (GVHD)

7. History of cardiovascular disease

8. History or presence of clinically relevant CNS pathology such as epilepsy, seizure, paresis, aphasia, stroke, severe brain injuries, dementia, Parkinson's disease, cerebellar disease, organic brain syndrome, or psychosis

9. Pregnant or nursing women

10. Use of the following:

    • Therapeutic doses of corticosteroids (defined as >20 mg/day prednisone or equivalent) within 7 days of leukapheresis or 72 hours prior to JCAR017 administration. Physiologic replacement, topical, and inhaled steroids are permitted.
    • Low dose chemotherapy (e.g., vincristine, rituximab, cyclophosphamide ≤300 mg/m2) given after leukapheresis to maintain disease control must be stopped ≥7 days prior to lymphodepleting chemotherapy.
    • Cytotoxic chemotherapeutic agents that are not considered lymphotoxic (see below) within 1 week of leukapheresis. Oral chemotherapeutic agents, including lenalidomide and ibrutinib, are allowed if at least 3 half-lives have elapsed prior to leukapheresis.
    • Lymphotoxic chemotherapeutic agents (e.g., cyclophosphamide, ifosfamide, bendamustine) within 2 weeks of leukapheresis.
    • Experimental agents within 4 weeks of leukapheresis unless no response or disease progression is documented on the experimental therapy and at least 3 half-lives have elapsed prior to leukapheresis
    • Immunosuppressive therapies within 4 weeks of leukapheresis and JCAR017 administration (e.g., calcineurin inhibitors, methotrexate or other chemotherapeutics, mycophenolyate, rapamycin, thalidomide, immunosuppressive antibodies such as anti-TNF, anti IL6, or anti-IL6R)
    • Donor lymphocyte infusions (DLI) within 6 weeks of JCAR017 administration
    • Radiation within 6 weeks of leukapheresis. Subjects must have progressive disease in irradiated lesions or have additional non-irradiated, PET-positive lesions to be eligible. Radiation to a single lesion, if additional non-irradiated PET-positive lesions are present, is allowed up to 2 weeks prior to leukapheresis.
    • Allo-HSCT within 90 days of leukapheresis

11. Prior CAR T-cell or other genetically-modified T-cell therapy, with the exception of prior JCAR017 treatment in this protocol for subjects receiving retreatment

12. Progressive vascular tumor invasion, thrombosis, or embolism

13. Venous thrombosis or embolism not managed on a stable regimen of anticoagulation

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
JCAR017 2-dose schedule (no longer accruing)	JCAR017 (lisocabtagene maraleucel) 2-dose schedule	Each cycle of JCAR017 (lisocabtagene maraleucel) will be administered as 2 intravenous (IV) injections
JCAR017 1-dose schedule	JCAR017 (lisocabtagene maraleucel) single-dose schedule	Each cycle of JCAR017 (lisocabtagene maraleucel) will be administered as 1 intravenous (IV) injection

Primary Outcome Measures

Name	Time	Method
Dose-limiting toxicities of JCAR017	28 days after first (single-dose schedule) or second (2-dose schedule) JCAR017 infusion	Physiological parameter
Treatment-related adverse events (AEs) as assessed by CTCAE v4.03	Up to 730 days after the final JCAR017 infusion	Physiological parameter
Objective response rate (ORR)	24 months	Lugano criteria

Secondary Outcome Measures

Name	Time	Method
Overall survival	Up to 15 years	Physiological parameter
Time to maximum concentration of JCAR017 (Tmax) in the peripheral blood	Up to 365 days after the final JCAR017 infusion	qPCR
Complete response (CR) rate	24 months	Lugano criteria
Duration of response	24 months	Lugano criteria
Progression-free survival (PFS)	24 months	Lugano criteria
Maximum concentration of JCAR017 (Cmax) in the peripheral blood	Up to 365 days after the final JCAR017 infusion	qPCR
Health-related quality of life	24 months	Questionnaire
Area-under-the-concentration-vs-time-curve (AUC) in the peripheral blood	Up to 365 days after the final JCAR017 infusion	qPCR

Trial Locations

Locations (14)

Local Institution - 0007; 🇺🇸 Duarte, California, United States

Local Institution - 0001; 🇺🇸 New York, New York, United States

Local Institution - 0021; 🇺🇸 Charlotte, North Carolina, United States

Local Institution - 0003; 🇺🇸 Chicago, Illinois, United States

Local Institution - 0019; 🇺🇸 Atlanta, Georgia, United States

Local Institution - 0029; 🇺🇸 Pittsburgh, Pennsylvania, United States

Local Institution - 0006; 🇺🇸 Birmingham, Alabama, United States

Local Institution - 0015; 🇺🇸 Boston, Massachusetts, United States

Local Institution - 0010; 🇺🇸 San Francisco, California, United States

Local Institution - 0020; 🇺🇸 Aurora, Colorado, United States

Local Institution - 0005; 🇺🇸 Boston, Massachusetts, United States

Local Institution - 0008; 🇺🇸 Omaha, Nebraska, United States

Local Institution - 0018; 🇺🇸 Seattle, Washington, United States

Local Institution - 0002; 🇺🇸 Houston, Texas, United States